In major reversal, Kennedy tells senators he won't take money from vaccine lawsuit
Kennedy’s commitment to walk away from the potential windfall is a major reversal for the nominee, who in his ethics plan ...
What to know about RFK Jr.'s financial ties with a personal industry law firm
Robert F. Kennedy Jr., Trump's pick to head the Department of Health and Human Services, faces scrutiny for fees he may earn ...
Kennedy Says He Will Give HPV Vaccine Lawsuit Proceeds to His Son
Robert F. Kennedy Jr. also disclosed that he had reached at least one settlement agreement with a company or individual that ...
IJR15h
Senate Committees Waging War On RFK Jr.’s MAHA Vision Are Knee Deep In Big Pharma, Food Industry Cash
Contentious hearings to consider Robert F. Kennedy Jr. to lead the Department of Health and Human Services this week have ...
Merck & Company Hold Rating: Promising Drug Developments Amid Uncertain Financial Outlook
Morgan Stanley analyst Terence Flynn has maintained their neutral stance on MRK stock, giving a Hold rating yesterday.Invest with Confidence: ...
Kennedy to divest interest from HPV vaccine lawsuits
President Donald Trump’s Health and Human Services nominee said he will divest his interest in lawsuits against an HPV ...
FiercePharma7h
Merck vaccine, Daiichi ADC win approval recommendations in busy week at EU's drug regulator
Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...
Merck Gets Key European Regulatory Backing for Capvaxive Vaccine
Merck on Friday said the recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use covers the 21-valent conjugate vaccine for immunization for the prevention ...
Deutsche Bank Sticks to Their Buy Rating for Merck KGaA (0O14)
In a report released today, Falko Friedrichs from Deutsche Bank maintained a Buy rating on Merck KGaA (0O14 – Research Report), with a price ...
Calendar: What investors need to know for the week ahead
A daily rundown of the economic reports and corporate earnings that will be grabbing the market’s attention in the week ahead ...
FierceBiotech15h
Novartis missed the PD-1 boat. Will it catch the bispecific wave?
After parting ways with BeiGene in 2023, Novartis effectively bowed out of the PD-1 race. | The rising class of bisepcifics ...
Merck's CAPVAXIVE gains CHMP nod for EU authorization
RAHWAY, N.J. - Merck & Co ., Inc. (NYSE:MRK) has received a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for its pneumococcal ...